Vol. 8 No. 1 (2021): January-December 2021

Published: 2021-12-28

Full Issue

Original Research Articles

  • Metastatic renal cancer: real-world evidence from a large Italian claims database

    Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Silvia Calabria, Anna Capponcelli, Antonella Pedrini, Maurizio Marangolo, Immacolata Esposito, Carmine Pinto, Nello Martini
    1-7
    DOI: https://doi.org/10.33393/grhta.2021.2178

  • Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain

    Néboa Zozaya, Almudena González-Domínguez, Natividad Calvente, Rita de la Plaza, Ana Herranz, Antonio Blanes, Miguel Tamayo
    8-13
    DOI: https://doi.org/10.33393/grhta.2021.2215

  • A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen

    Sergio Iannazzo
    14-21
    DOI: https://doi.org/10.33393/grhta.2021.2193

  • The future of Funds for Innovative Medicines: results from a Delphi Study

    Claudio Jommi, Patrizio Armeni, Arianna Bertolani, Francesco Costa, Monica Otto
    22-28
    DOI: https://doi.org/10.33393/grhta.2021.2219

  • Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

    Marco Chiumente, Alberto Russi, Federica Todino, Daniele Mengato, Marina Coppola, Melania Rivano, Angelo Claudio Palozzo, Claudio Jommi
    29-34
    DOI: https://doi.org/10.33393/grhta.2021.2202

  • Costs of the management of hemophilia A with inhibitors in Spain

    Santiago Bonanad, María Teresa Álvarez, Ramiro Núñez, José Luis Poveda, Beatriz Gil, Elena Ruíz-Beato, Ana Durán, Yoana Ivanova, Inés Pérez-Román, Almudena González-Domínguez
    35-42
    DOI: https://doi.org/10.33393/grhta.2021.2234

  • Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy

    Giovanni Di Minno, Roberto Ravasio
    43-52
    DOI: https://doi.org/10.33393/grhta.2021.2191

  • Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

    Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi
    53-57
    DOI: https://doi.org/10.33393/grhta.2021.2222

  • The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

    Stefano Fagiuoli, Matteo Ruggeri, Filipa Aragao, Rob Blissett
    58-66
    DOI: https://doi.org/10.33393/grhta.2021.2183

  • Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

    Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi
    69-79
    DOI: https://doi.org/10.33393/grhta.2021.2267

  • Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

    Mario Boccadoro, Patrizia Berto, Sara Bringhen, Elena Zamagni, Patrizia Tosi, Nicola Cascavilla, Nicola Giuliani, Donato Mannina, Renato Zambello, Francesca Patriarca, Vittorio Montefusco, Mariella Grasso, Francesco Di Raimondo, Massimo Offidani, Maria Teresa Petrucci, Pellegrino Musto
    80-86
    DOI: https://doi.org/10.33393/grhta.2021.2245

  • Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia

    Michele Basile, Filippo Rumi, Americo Cicchetti
    87-95
    DOI: https://doi.org/10.33393/grhta.2021.2238

  • Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

    Michele Basile, Lorenzo Somaini, Americo Cicchetti
    96-104
    DOI: https://doi.org/10.33393/grhta.2021.2237

  • Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population

    Filippo Rumi, Michele Basile, Americo Cicchetti
    105-113
    DOI: https://doi.org/10.33393/grhta.2021.2247

  • Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

    Paolo Gisondi, Francesco Loconsole, Paola Raimondo, Roberto Ravasio
    120-130
    DOI: https://doi.org/10.33393/grhta.2021.2258

  • The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective

    Luis J. Pastor-Quirós, Edgar P. Correa-Díaz
    140-146
    DOI: https://doi.org/10.33393/grhta.2021.2273

  • Evaluation of epidemiological and economic consequences due to the delay in treatment of hiv-positive patients caused by the covid-19 pandemic

    Andrea Marcellusi, Chiara Bini, Massimo Andreoni, Andrea Antinori, Francesco Saverio Mennini
    147-154
    DOI: https://doi.org/10.33393/grhta.2021.2279

  • Cost-utility analysis of evolocumab in patients with ASCVD in Italy

    Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Emanuela Arcangeli, Laura Martinez, Francesc Sorio Vilela, Francesco Saverio Mennini
    155-167
    DOI: https://doi.org/10.33393/grhta.2021.2255

Correspondence

Point of View

  • Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?

    Claudio Jommi, Antonio Addis, Nello Martini, Elena Nicod, Marcello Pani, Annalisa Scopinaro, Sabine Vogler
    114-119
    DOI: https://doi.org/10.33393/grhta.2021.2278

  • New drug pricing criteria in Italy: considerations and proposals to support value and innovation

    Francesca Patarnello, Federico Villa
    131-133
    DOI: https://doi.org/10.33393/grhta.2021.2207

  • Real-world data: how they can help to improve quality of care

    Giovanni Corrao, Giovanni Alquati, Giovanni Apolone, Andrea Ardizzoni, Giuliano Buzzetti, Giorgio W. Canonica, Pierfranco Conte, Elisa Crovato, Francesco Damele, Carlo La Vecchia, Aldo P. Maggioni, Alberto Mantovani, Michele Marangi, Walter Marrocco, Andrea Messori, Alessandro Padovani, Alessandro Rambaldi, Walter Ricciardi, Francesco Ripa di Meana, Federico Spandonaro, Valeria Tozzi, Giuseppe Mancia
    134-139
    DOI: https://doi.org/10.33393/grhta.2021.2286